(Total Views: 596)
Posted On: 11/15/2025 5:55:10 PM
Post# of 158792
Re: USS JOHNSTON #158484
Speaking of an unfiltered change of ideas;
A recent Dr. Jay interview...comes
"Sustained remission five years later is absolutely remarkable. It is retrospective, but, it is remarkable nonetheless"
You can shoot me for blasphemy,...but aren't All results...from All trials retrospective.
It doesn't denigrate,...the facts of the Five Alive.
Further on,...
"We do not see a dominant safety signal or concern,...which is NOT something you can say about another cancer candidate therapeutic." Now that was a shot over the bows of BP's shipping lanes.
"So that's where the checkpoint inhibitor,... Keytruda comes in"...( naming the players) and that is that the women who received Leronlimab had a breakdown in the tumor environment, then, secreted PDL-1 in an effort to repel the immune system.
The women who got the checkpoint inhibitor to block the action of the protein, PDL-1 they're the ones who survived."
"So what Cytodyn has stumbled into is,... that's why I use the word paradigm shift. It really is a game-changer, potentially in Solid-tumor Oncology"
I think We have a clear sight now to where this company needs to go and how to get this drug approved for patients"
"Stumbled into"...amusing choice of words,...but that's Biotech for you. This is now a retrospective post.
A recent Dr. Jay interview...comes
"Sustained remission five years later is absolutely remarkable. It is retrospective, but, it is remarkable nonetheless"
You can shoot me for blasphemy,...but aren't All results...from All trials retrospective.
It doesn't denigrate,...the facts of the Five Alive.
Further on,...
"We do not see a dominant safety signal or concern,...which is NOT something you can say about another cancer candidate therapeutic." Now that was a shot over the bows of BP's shipping lanes.
"So that's where the checkpoint inhibitor,... Keytruda comes in"...( naming the players) and that is that the women who received Leronlimab had a breakdown in the tumor environment, then, secreted PDL-1 in an effort to repel the immune system.
The women who got the checkpoint inhibitor to block the action of the protein, PDL-1 they're the ones who survived."
"So what Cytodyn has stumbled into is,... that's why I use the word paradigm shift. It really is a game-changer, potentially in Solid-tumor Oncology"
I think We have a clear sight now to where this company needs to go and how to get this drug approved for patients"
"Stumbled into"...amusing choice of words,...but that's Biotech for you. This is now a retrospective post.
(20)
(0)
